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Abstract: Inhibition of p53-MDM2/MDMX interaction is considered to be a promising 
strategy for anticancer drug design to activate wild-type p53 in tumors. We carry out 
molecular dynamics (MD) simulations to study the binding mechanisms of peptide and 
non-peptide inhibitors to MDM2/MDMX. The rank of binding free energies calculated by 
molecular mechanics generalized Born surface area (MM-GBSA) method agrees with one 
of the experimental values. The results suggest that van der Waals energy drives two kinds 
of inhibitors to MDM2/MDMX. We also find that the peptide inhibitors can produce more 
interaction contacts with MDM2/MDMX than the non-peptide inhibitors. Binding mode 
predictions based on the inhibitor-residue interactions show that the π–π, CH–π and   
CH–CH interactions dominated by shape complimentarity, govern the binding of the 
inhibitors in the hydrophobic cleft of MDM2/MDMX. Our studies confirm the residue 
Tyr99 in MDMX can generate a steric clash with the inhibitors due to energy and structure. 
This finding may theoretically provide help to develop potent dual-specific or   
MDMX inhibitors. 
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1. Introduction 
The tumor suppressor protein p53, “the guardian of the genome,” plays a key role in maintaining 
the integrity of the genome by inducing cell cycle arrest and apoptosis in response to stress [1]. It can 
protect higher organisms from cancer by activating its original function [2]. However, the oncoproteins 
MDM2 and MDMX negatively regulate the activity of the tumor suppressor p53 by binding to the  
N-terminal transactivation domain of p53 [3–6]. In fact, the overexpressions of MDM2 and MDMX 
contribute to the loss of p53 activation and tumor survival in tumors [7,8]. Almost 50% of all human 
cancers are due to invalidation of the p53 function caused by deletions or mutations in the   
DNA-binding domain of p53 [9]. Thus, the p53-MDM2/MDMX interaction becomes an attractive 
molecular target for cancer therapy. 
Figure 1. Sequence and structure of the binding domain of MDM2/MDMX to p53.   
(A) The sequence alignment of MDM2 with MDMX; (B) Stereoview of superimposed 
structures of pDI6W-MDM2 (green/orange) and pDI6W-MDMX (yellow/light blue) in a 
cartoon diagram. The sign “'” represents the second structure belonging to MDMX. In 
Figure 1B, α β and l represent α-helix, β-sheet and loop, respectively. 
 
Recent studies show that MDMX is not only highly homologous (55%) to MDM2 (Figure 1A), but 
also shares a common structural sequence of a ααβαβα topology in overall structures of human Int. J. Mol. Sci. 2012, 13 2178 
 
 
MDM2/MDMX (Figure 1B) [10–12]. Superposition of MDM2 and MDMX displays a large structural 
difference in α4 (α'4) helix, stemming from a change of His96 of MDM2 to Pro95 of MDMX [13]. 
Earlier biochemical studies using p53 peptide have proven that MDM2 binds to p53 with 10-fold 
higher affinity than MDMX [14]. Previous insights into the inhibition of the p53-MDM2/MDMX 
interaction also reveal that the most of the peptide and non-peptide inhibitors, such as Nutlins and  
MI-219, provide strong anti-tumor potential of MDM2 inhibitors, but they do not efficiently inhibit  
the interaction of MDMX with p53 [6,14–24]. Lately, a 15-residue p53 peptide determined by   
Popowicz  et al. shows similar affinity to MDM2/MDMX [25]. This provides a possibility of 
developing dual inhibitors of the p53-MDM2/MDMX interaction. Furthermore, this result has been 
supported by the studies of several other groups [16,26–32]. 
Understanding the binding mechanisms of the peptide and non-peptide inhibitors to 
MDM2/MDMX at an atomic level may facilitate the development of potent dual inhibitors inhibiting 
the p53-MDM2/MDMX interaction and provide valuable information about the structure-affinity 
relationships of the p53-MDM2/MDMX complexes. A few computational studies have been 
performed for this purpose [26,33,34]. In this work, we selected a peptide inhibitor pDI6W and a  
non-peptide inhibitor WK23 to probe the difference in the binding mechanisms of two kinds of 
inhibitors to MDM2/MDMX. WK23 is an inhibitor based on four aromatic groups studied by 
Popowicz G.M. et al. and able to efficiently fill the binding pockets of MDM2/MDMX, its median 
inhibitory concentration (IC50) values to MDM2/MDMX are 1.17 and 36 μM, respectively [6]. pDI6W 
is a 12-residue peptide inhibitor (LTFEHWWAQLTS) designed by Phan J. et al. with IC50 values of 
36 and 250 nM to MDM2/MDMX, respectively [31]. Both of the two inhibitors have big differences in 
binding free energies to MDM2 and MDMX [6,31]. Thus it is significant to explore the reason for this 
difference for the design of dual inhibitors. Figure 2 depicts the structures of two inhibitors and points 
out the parts imitating three residues of p53: Phe19', Trp23', and Leu26', inserted into the hydrophobic 
groove in MDM2/MDMX. 
Binding free energy calculations have been proven to be powerful and valuable tools for 
understanding the binding mechanisms of inhibitors to proteins. To date, several effective methods 
have been proposed to calculate the binding free energies of protein inhibitors: free energy 
perturbation (FEP) [35], thermodynamic integration (TI) [36,37] and MM-PB(GB)SA etc. [21,38–41]. 
Although FEP and TI should give more accurate binding free energies, they are restricted to closely 
related chemical structures of inhibitors. Furthermore, MM-PB(GB)SA method has been used successfully 
in explaining protein-protein and protein-inhibitor interactions [28,42–47]. In this method, polar 
solvation free energy calculated by the Possion-Boltzmann (PB) equation leads MM-PBSA calculations, 
while obtained by the generalized Born equation is the so-called MM-GBSA calculations [48–50]. 
Thus, in this work, the MM-GBSA method combined MD simulation was applied to calculate the 
binding free energies of two inhibitors to MDM2/MDMX. By the calculations of the binding free 
energy, the inhibitor-residue interaction and alanine scanning, we expect that the following three aims 
can be achieved: (1) to understand the difference in the binding modes of two different kinds of 
inhibitors; (2) to illuminate the main force to drive the bindings of inhibitors in the hydrophobic cleft 
of MDM2/MDMX; (3) to explore the cause of a big difference in the binding free energy of the same 
inhibitor to MDM2/MDMX with high homology and similar structure. We also expect that this study Int. J. Mol. Sci. 2012, 13 2179 
 
 
can provide important hints for the design of the potent dual inhibitor inhibiting the interaction of p53 
with MDM2/MDMX. 
Figure 2. Structures of inhibitors. (A) Non-peptide inhibitor WK23 is shown in sticks and 
green; (B) peptide inhibitor pDI6W is shown in cartoon and light blue, and three residues 
are shown in stick and green. 
 
2. Results and Discussion 
2.1. System Stability During MD Simulations 
To evaluate the reliable stability of MD trajectories, RMSD of backbone atoms relative to the initial 
minimized structure through the phase of the simulation was plotted in Figure 3. One can see that four 
complexes have reached the equilibrium about after 4.5 ns of the simulation phase. According to 
Figure 3, the RMSD values of WK23-MDM2, pDI6W-MDM2, WK23-MDMX and pDI6W-MDMX 
complexes are 1.07, 1.08, 1.19 and 1.27 Å, respectively, with a deviation of lower than 0.65 Å. This 
result shows that the trajectories of MD simulations for four complexes after the equilibrium are 
reliable for post analyses. It was observed from Figure 3 that the RMSD values of two complexes 
involving MDM2 are lower than MDMX. 
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Figure 3. Root-mean-square deviations (RMSD) of backbone atoms relative to their initial 
minimized structures as function of time. 
 
2.2. Superimposition Analyses 
To acquire an atomic view of the difference between the MD-simulated structures and crystal 
structures, the structures of the MD-simulated complexes from the last 500 ps of MD simulations at an 
interval of 10 ps were superimposed with the crystal structures (plotted in Figure 4). As shown in 
Figure 4, the residue Tyr100 in the helix α4 of MDM2 moves obviously, but except for the slight shift 
of the position T1 in the inhibitor pDI6W, the MD-simulated structures of MDM2 agree well with the 
crystal structures (Figure 4A,C). In the case of the pDI6W-MDMX complex, the residue Tyr99 in the 
helix α'4 of MDMX and pDI6W have slight shifts from the crystal structure, though the helix α'4 and 
the end T2 of α'2 in MDMX obviously depart from the crystal structure. Although the residue Tyr99, 
the ring R1 and R2 of the inhibitor WK23 and the helix α'4 highly deviate in their crystal structures in 
the case of the WK23-MDMX complex, the remainder of MDMX takes the same orientation as in the 
crystal structure. To sum up, the superimposition analyses suggest that the MD-simulated structures of 
MDM2 have smaller deviation from the crystal structure than MDMX, which agrees basically with the 
previous RMSD analyses. 
2.3. Calculations of Binding Free Energies 
To further evaluate the difference in the binding modes of the inhibitors to MDM2/MDMX and 
obtain detailed insights into the contribution of each component to the inhibitor-protein binding, the 
binding affinities of the inhibitors to MDM2/MDMX were estimated by performing MM-GBSA 
calculations based on a single-trajectory MD simulation. Because the radius parameter of chlorine 
atoms is missing for MM-GBSA module in Amber 10, we add the radii of 1.75 Å for chlorine to pbsa 
program in Amber [51]. The calculated results and experimental data (ΔGexp) were summarized in 
Table 1. The predicted binding free energies of pDI6W-MDM2, pDI6W-MDMX, WK23-MDM2 and 
WK23-MDMX complex are −21.93, −19.74, −16.81 and −14.89 kcal·mol
−1, respectively. Furthermore, it is 
encouraging that the ranking of the experimental binding free energies are consistent with our 
predictions, which suggests the MD-simulation models and computational protocol tested in this study 
is reliable. Int. J. Mol. Sci. 2012, 13 2181 
 
 
Figure 4. Crystal structures were superimposed on the average structure from the last 500 ps 
of molecular dynamics simulation at an interval of 10 ps, (A) for the pDI6W-MDM2 
complex; (B) for the pDI6W-MDM2 one; (C) for the WK23-MDM2 one; and (D) for the 
WK23-MDMX one. In the average structure, protein, inhibitor and Tyr100 (Tyr99) are 
shown in light orange, cyan and green, respectively. In the crystal structure, the protein, 
inhibitor and Tyr100 (Tyr99) are displayed in light blue, violet and yellow. The residue 
Leu26' is from pDI6W and second structure labeled by α' belongs to MDMX. T1 
represents the residues 49–51 in MDMX and T2 indicates the residues 24 and 25 in pDI6W. 
 
Table 1. Binding free energies computed by MM-GBSA method 
a. 
Components 
b 
pDI6W + MDM2  pDI6W + MDMX  WK23 + MDM2  WK23 + MDMX 
mean std 
c Mean  std 
c mean std 
c mean std 
c 
ΔGele  −135.20 0.41 −144.89 0.32 −0.95 0.01 −1.78 0.05 
ΔGvdw  −67.76 0.16 −65.49 0.17  −40.05 0.21 −36.26 0.31 
ΔGpol 149.67  0.31  169.18  0.36  11.05  0.08  12.18  0.10 
ΔGnopol  −9.18 0.05 −9.11 0.02  −5.36 0.21 −5.41 0.02 
ΔGele + pol 23.65  0.20  24.29  0.20  10.09  0.06  10.39  0.07 
ΔGgb  −53.29 0.23 −50.31 0.24  −35.31 0.14 −31.28 0.14 
−TΔS 31.36  0.12  30.57  0.21  18.50  0.11  15.61  0.18 
ΔGbind  −21.93  −19.74   −16.81  −14.89  
ΔGexp 
d  −10.5  −9.73   −8.26  −6.08  
a All values are given in kcal·mol
−1; 
b Component: ΔGele: electrostatic energy in the gas phase; ΔGvdw: van der 
Waals energy; ΔGnopol: non-polar solvation energy; ΔGpol: polar salvation energy; ΔGele+pol = ΔGele + ΔGpol: 
polar interaction energy; ΔGgb = ΔGvdw + ΔGnopol + ΔGele+pol;  −TΔS: total entropy contribution;   
ΔGbind = ΔGgb − TΔS; 
c Standard errors of the mean; 
d The experimental values ∆Gexp were derived from the 
experimental IC50 values in References [14,24] by using the equation ∆G ≈ −RTlnIC50. Int. J. Mol. Sci. 2012, 13 2182 
 
 
As shown in Table 1, the major favorable contributors to the inhibitor binding are van der Waals 
energies (∆Gvdw). Non-polar solvation energies (∆Gnopol), which correspond to the burial of SASA 
upon binding, also provide important contributions to binding. However, the contributions of the 
entropy changes to the free energies (−T∆S) impair the bindings of two inhibitors to MDM2/MDMX. 
Although the electrostatic terms (∆Gele) favored inhibitor binding, these favorable contributions were 
completely screened by the unfavorable stronger polar solvation energies (∆Gpol). It is noted that the 
electrostatic interaction of pDI6W with MDM2/MDMX is two times stronger than van der Waals 
energies, while the electrostatic terms of the interaction between WK23 and MDM2/MDMX is much 
weaker than van der Waals energy. Thus, it is concluded van der Walls energy dominates the bindings 
of the inhibitors in the hydrophobic cleft of two oncoproteins. This result agrees with the previous 
studies of several groups [6,26,34]. 
Two interesting phenomena are observed from Table 1. (1) Compared with the interactions of the 
non-peptide inhibitor WK23 with MDM2/MDMX, the electrostatic interaction and van der Waals term 
of pDI6W with MDM2 and MDMX are much stronger than WK23. This result shows that the peptide 
inhibitor pDI6W can produce more interaction contacts with MDM2/MDMX than the non-peptide 
inhibitor WK23; (2) The van der Waals interactions of pDI6W and WK23 with MDMX are 2.17 and 
3.79 kcal·mol
−1, weaker than one of pDI6W and WK23 with MDM2, respectively. Despite a high 
homology and similar structure of MDM2/MDMX (Figure 1B), the bindings of the same inhibitor 
result in an obvious decrease in van der Waals energy. To explain this phenomenon, we analyzed the 
conformations of all residues in the helix α4/α'4 from MDM2/MDMX and observed that the residue 
Tyr99 in MDMX takes very different side chain orientation from the residue Tyr100 in MDM2   
(Figure 5). For MDM2, the side chain of Tyr100 points outward and accommodates the bindings of 
Leu26' and the ring R1 of WK23. However, for MDMX, the side chain of Tyr99 orients toward Leu26' 
and the ring R1 of WK23, which shows that Tyr99 prevents the inhibitor from moving into the deep 
cleft between α'2 and α'4 of MDMX, and generates less inhibitor-MDMX contacts, this leads to   
a decrease in van der Waals energy. The above analyses basically agree with the previous   
studies [26,31,32]. 
Figure 5. Stereoview of superimposed structures of inhibitor-MDM2 complex and 
inhibitor-MDMX complex. MDM2/MDMX and pDI6W are displayed in a cartoon mode, 
MDM2 is shown in light orange and MDMX in light blue, Leu26', Tyr99 of MDMX and 
Tyr100 of MDM2 are shown in stick. (A) pDI6W-MDM2/MDMX complex;   
(B) WK23-MDM2/MDMX complex. The character “x” before the residue represents this 
residue belongs to MDMX. 
 Int. J. Mol. Sci. 2012, 13 2183 
 
 
2.4. Binding Mode Predictions of Inhibitors to MDM2/MDMX 
To gain a more-detailed insight into the effects of the specific active site residues on the inhibitor 
binding, structure and binding mode, analyses were carried out to complement the previous energy 
analyses. Hydrogen bond analyses based on MD simulations were also performed and the information 
was listed in Table 2. The decomposition analysis generates an inhibitor-protein interaction spectrum 
showing the interactions of the inhibitors with individual residues (Figure 6). Figure 7 depicts the 
relative positions of the inhibitors and correlated residues in the binding complex by using the lowest 
energy structure taken from the MD trajectories.  
Table 2. Hydrogen bonds formed between the inhibitors and MDM2/MDMX. 
Protein Donor 
a Acceptor  Distance(Å) 
b Angle(°) 
b Occupancy(%) 
c 
MDM2 
Trp23'-NE1-HE1 Leu54-O  2.92  146.79  97.20 
Phe19'-N-H Gln72-OE1  3.01 151.71 71.34 
WK23-N8-H75 Leu54-O  2.90  154.12  98.95 
MDMX 
Trp23'-NE1-HE1 Met53-O  2.89  140.29  98.76 
Phe19'-N-H Gln71-OE1  3.01 150.94 69.66 
WK23-N8-H103 Met53-O  2.92  153.75  99.29 
a The sign “'” represents the residue belonging to the peptide inhibitor pDI6W; 
b The hydrogen bonds are 
determined by the acceptor···donor atom distance of less than 3.5 Å and acceptor···H-donor angle of greater 
than 120°; 
c occupancy(%): to evaluate the stability and the strength of the hydrogen bond. 
According to Figure 6A, eleven residues are involved in the main binding attractions, with the 
inhibitor-residue interaction stronger than 1 kcal·mol
-1 for the MDM2-pDI6W complex. Structurally, 
the phenol of the residue Tyr67 and the phenyl of Phe19' generate an almost paralleled π–π interaction 
(Figure 7A) and the distances of carbon atoms between two rings range from 3.65 to 6.79 Å [52], 
which produces an interaction energy of −2.07 kcal·mol
−1 between Phe19' and Tyr67. The alkyls of 
Ile61 and Met62 form many CH–π contacts with the phenyl of Phe19' [53,54], which respectively 
corresponds to two interaction energies of −1.93 and −1.42 kcal·mol
−1 of pDI6W with Ile61 and 
Met62. In addition, the nitrogen atom N in the backbone of Phe19' provides a hydrogen atom H to 
construct a hydrogen bond with OE1 of Gln72 (Figure 7A and Table 2), which leads to a weak 
favorable binding energy of −0.88 kcal·mol
−1. The occupancy of 71.34% of this hydrogen bond shows 
that it is stable during the simulation. Thus, four residues Tyr67, Met62, Ile61 and Gln72 build a 
hydrophobic pocket that matches the hydrophobic phenyl of Phe19' to form a shape complementarity. 
The interaction energy of pDI6W with Val93 is −3.68 kcal·mol
−1 and is the strongest among all 
residues, and this favorable energy may partly come from the CH–π contacts between the indole of 
Trp23' and the alkyl of Val93 and partly from the CH–CH contacts [53,54] between the alkyl of Leu26' 
and Val93. Except for the CH–π interactions from the indole of Trp23' with the alkyl of Leu54 and the 
CH group of Gly58, the atom NE1 of Trp23' forms one hydrogen bond with the backbone carbonyl 
oxygen of Leu54 (Figure 7A), the distance between the corresponding oxygen and nitrogen atoms is 
2.91 Å and the occupancy is 97.20% (Table 2), which shows that Trp23' produces the interaction 
energies of −3.27 and −1.3 kcal·mol
−1 with the two residues Leu54 and Gly58, respectively. Therefore, Int. J. Mol. Sci. 2012, 13 2184 
 
 
Leu54, Gly58 and Val93 form the second hydrophobic pocket to which Trp23' binds. The binding 
energies of pDI6W to His96 and Ile99 are −1.73 and −1.29 kcal·mol
−1, respectively. This result is in 
agreement with the hydrophobic CH–π interaction between the alkyl of Leu26' and the imidazole of 
His96 and the hydrophobic CH–CH contacts between two alkyls of Leu26' and Ile99 (Figure 7A). 
Thus, four residues Leu54, Val93, His96 and Ile99 encircle the third hydrophobic pocket that 
accommodates the hydrophobic side chain of Leu26'. In addition, the imidazole of His73 and the 
indole of Trp22' form a hydrophobic π–π interaction of −2.06 kcal·mol
−1, and a strong hydrophobic 
CH–CH interaction of −3.11 kcal·mol
−1 also exists between Thr27' and Lys51 (Figure 6A and Figure 7A). 
Figure 6. Inhibitor-residue interaction spectrum of (A) pDI6W-MDM2 complex; 
(B)  pDI6W-MDMX complex; (C) WK23-MDM2 complex; and (D) WK23-MDMX 
complex based on MM-GBSA method. The residues with interaction energy of larger than  
1 kcal·mol
−1 are labeled. The character “x” before the residue represents this residue 
belongs to MDMX. 
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Figure 7. Geometries of key residues, which produce some favorable interactions with two 
inhibitors, are plotted in the complexes according to the lowest-energy structure from the 
MD trajectory. (A) pDI6W-MDM2 complex; (B) pDI6W-MDMX complex;   
(C) WK23-MDM2 complex; and (D) WK23-MDMX complex. The dashed line represents 
a hydrogen bond between the inhibitor and protein. 
 
For the WK23-MDM2 complex, the number of the residues involving the Wk23-MDM2 interaction 
is less than the pDI6W-MDM2 complex. According to Figure 6C and Figure 7C, WK23 loses the 
hydrogen bond between Phe19' and Gln72 and the hydrophobic interactions of pDI6W with the 
residues Thr27' and Trp22'. The rest analysis is similar to the pDI6W-MDM2 complex. As seen from 
Figure 7A,C, the orientation of the residue Tyr100 points outward and the third hydrophobic pocket 
can be well formed to accommodate the side chain of Leu26' and the ring R4 of WK23. 
In the pDI6W-MDMX binding complex (Figure 6B and Figure 7B), the residues Ile60, Met53, 
Tyr66 and Gln71 shape the first hydrophobic pocket that matches the hydrophobic phenyl of Phe19'. 
Similar to the pDI6W-MDM2 binding, the pDI6W-Tyr66 binding energy is −2.25 kcal·mol
−1, which 
structurally agrees with the strong π–π interaction between the phenyl of Phe19' and the phenol of 
Tyr66. The hydrogen bond between the atom N of Phe19' and the atom OE1 of Gln71 also contributes 
a weak favorable energy (Figure 7B and Table 2). The CH–π contacts between the alkyls of Ile60 and 
Met63 and the phenyl of Phe19' may result in the energy contributions of −1.52 and −2.05 kcal·mol
−1, 
respectively. The alkyl of Met53 not only produces many CH–π contacts with the indole of Trp23' and 
CH–CH interactions with the alkyl of Leu26', but also the atom O of Met53 forms a hydrogen bond 
with the atom NE1 of Trp23' with the occupancy of 98.76%, which results in the pDI6W-Met53 Int. J. Mol. Sci. 2012, 13 2186 
 
 
binding energy of −2.92 kcal·mol
−1 (Figure 6B, Figure 7B and Table 2). The indole of Trp23' contacts 
the imidazole of His54 to generate the hydrophobic and aromatic stacking interaction of   
−1.59 kcal·mol
−1, and also is close to the CH group of Gly57 to form the CH–π interaction of   
−1.52 kcal·mol
−1 (Figure 6B and Figure 7B). In addition, the pDI6W-Val92 interaction energy is   
−2.31 kcal·mol
−1, which may mainly come from the CH–π interaction with Trp23' and the CH–CH 
contacts with Leu26'. Thus, Met53, His54, Gly57 and Val92 build the second hydrophobic pocket that 
accommodates the indole of Trp23'. According to Figure 6B, the interaction energy of pDI6W with 
Leu98 is −0.73 kcal·mol
−1, which structurally corresponds to a number of CH–CH contacts between 
the alkyls of Leu26' and Leu98 (Figure 7B). The aromatic ring of Pro95 is near the alkyl of Leu26', 
which may be the main source of the pDI6W-Pro95 interaction (−1.31 kcal·mol
−1). Thus, the residues 
Met53, Val92, Pro95 and Leu98 form the third hydrophobic pocket that matches the hydrophobic alkyl 
of Leu26'. As seen from Figure 7B, the residue Tyr99 points toward Leu26' and prevent the alkyl of 
Leu26' from moving into the deep of the pocket. Just for this reason, the interaction energies of pDI6W 
with the three residues Val92, Pro95 and Leu98 in MDMX are 2.37, 0.62 and 0.56 kcal·mol
−1 weaker 
than one of pDI6W with Val93, His96 and Ile99 in MDM2, respectively. This result shows that Tyr99 
certainly forms a steric clash with Leu26' and produces an important effect on the inhibitor-protein 
binding, which has been proven by the previous analyses of binding free energies. In addition, the 
strong CH–CH contacts between Lys50 and Thr27' also provide favorable contribution to the   
pDI6W-MDMX binding. 
For the WK23-MDMX complex, the binding mode prediction of WK23 to MDMX is similar to the 
pDI6W-MDMX complex. It is observed that the number of the residues involving the WK23-MDMX 
interaction is less than the pDI6W-MDMX complex. By comparing Figure 6D with Figure 6B, WK23 
loses the hydrogen bond between Phe19' and Gln71 and the WK23-Lys51 interaction. Because the 
residue Tyr99 orients toward the ring R4 of WK23, Tyr99 prevents the ring R4 of WK23 into the deep 
of the hydrophobic pocket shaped by Met53, Val92, Pro95 and Leu98, Which is the main reason that 
the interaction energy of WK23 with Pro95 and Leu98 in MDMX is 0.87 and 0.42 kcal·mol
−1 weaker 
than one of WK23 with His96 and Ile99 in MDM2, despite the binding energy of WK23 with Val92 of 
MDMX slightly higher than one of WK23 with Val93 of MDM2. This result shows that the orientation 
conflict of Tyr99 with the ring R4 of WK23 can produce important influence on the inhibitor binding. 
This work basically agrees with the previous studies [6,26,27,31]. 
Based on the above analysis, three important conclusions can be obtained: (1) the peptide inhibitors 
can generate more interaction contacts with MDM2/MDMX than the non-peptide inhibitors; (2) The 
steric clash formed by Tyr99 leads to the decrease in the inhibitor-MDMX binding affinity; (3) The  
π–π, CH–π and CH–CH interactions dominated by the shape complementarity drive the bindings of the 
inhibitors in the hydrophobic cleft of MDM2/MDMX. 
2.5. Computational Alanine Scanning 
We performed alanine scanning on the inhibitor-MDM2/MDM2 complex to validate the 
contributions of free energy components to the binding. Because the polar solvation energy (ΔGpol) is 
closely related to the electrostatic term (ΔGele), these two components were combined into a 
component: polar interaction component (ΔGele + pol). Figure 8 shows the binding free energies and Int. J. Mol. Sci. 2012, 13 2187 
 
 
energy components of the complex with the mutated and wild protein, which includes van der Waals 
energy (ΔGvdw), non-polar solvation free energy (ΔGnopol), polar interaction component (ΔGele + pol) and 
binding free energy (ΔGgb). The alanine scanning results in different effects on the separate energy 
component. As seen in Figure 8, the alanine scanning hardly influences the non-polar solvation energy 
component and polar interaction energy. However, it produces an obvious effect on van der Waals 
energy and the binding free energy. This is because the alanine scanning reduces the hydrophobic 
chain of the selected residues and causes the decrease in the number of van der Waals contacts 
between two inhibitors and MDM2/MDMX. Furthermore, Figure 8 suggests that the decrease in the 
binding free energy mainly comes from the decrease in van der Waals energy. Thus, it is concluded 
that van der Waals energy play an important role in the bindings of the inhibitors in the hydrophobic 
cleft of MDM2/MDMX, which is consistent with the previous free energy analyses. 
Figure 8. Changes of binding free energy components caused by alanine scanning. Binding 
of inhibitors to wild-type protein and mutated protein are represented by black and red, 
respectively. (A) pDI6W-MDM2 complex; (B) pDI6W-MDMX complex;   
(C) WK23-MDM2 complex; and (D) WK23-MDMX complex. Components are as 
follows: 1 van der Waals energy (ΔEvdw), 2 non-polar solvation energy (ΔGnopol), 3 polar 
interaction energy (ΔGpol + ele), 4 binding free energy (ΔGgb). 
 
To identify the binding hot spots of the protein and gain further insight into the contribution of each 
alanine mutation, we also calculated the change of the inhibitor-residue interaction caused by the 
alanine scanning (plotted in Figure 9). According to Figure 9, the alanine scanning leads to the 
decreases of more than 0.7 kcal·mol
−1 in the interaction energies of the inhibitor with eight residues 
(Lys51, Leu54, Ile61, Met62, Tyr67, Val93, His96 and Ile99) for the pDI6W-MDM2 complex, four 
residues (Leu54, Ile61, Val93 and Ile99) for the WK23-MDM2 complex, six residues (Lys50, His54, 
Ile60, Met61, Tyr66 and Val92) for the pDI6W-MDM complex and four residues (Met53, Ile60, Val92 
and Leu98) for the WK23-MDMX complex. This result is due to the decrease in the number of CH–π 
and CH–CH contacts or the loss of π–π interaction between the inhibitor and MDM2/MDMX caused 
by the alanine scanning. Although the oxygen atoms of Leu54 or Met53 form a hydrogen bond with Int. J. Mol. Sci. 2012, 13 2188 
 
 
the inhibitors, this oxygen atom belongs to the protein backbone. Thus, the alanine scanning does not 
influence this hydrogen bond. In a word, the π–π, CH–π and CH–CH interactions of the inhibitors with 
the proteins govern the bindings of the inhibitors in the hydrophobic cleft of MDM2/MDMX, which 
agrees with the previous analysis of binding modes. 
Figure 9. Changes of inhibitor-residue interaction energy caused by alanine scanning. 
Gray and red are used to represent the interactions of inhibitor with the residues of   
wild-type protein and mutated protein, respectively. (A) pDI6W-MDM2 complex; 
(B)  WK23-MDM2 complex; (C) pDI6W-MDMX complex; and (D) WK23-MDMX 
complex. 
 
3. Experimental Section 
3.1. System Preparation  
Initial structures of pDI6W-MDM2, pDI6W-MDMX and WK23-MDM2 complexes used in current 
computational studies came from X-ray structures (PDB entry: 3JZR, 3JZP, and 3LBK) in the protein 
data bank (PDB) [6,31]. The structure of WK23-MDMX complex was obtained by modifying the 
WK298-MDMX structure (PDB entry: 3LBJ) [6]. All missing hydrogen atoms of MDM2/MDMX and 
pDI6W were added by using the leap module in Amber10 software package [55]. All crystal water 
molecules in the PDB files were kept in the starting model. The force field ff99SB was applied to 
produce the force field parameters of the protein and crystal water molecules. The electrostatic 
potential of WK23 was calculated by using the Gaussian 98 package at the HF/6-31G* level [56]. 
Atom-centered partial charges were derived by using the RESP fitting technique in the AMBER [57]. 
The general AMBER force field (GAFF) [58] was used for the force field parameters of WK23, 
including the Lennard-Jones, torsion, bond angle terms. An appropriate number of chloride 
counterions were placed around the complex to neutralize the charges of the systems. Then, each 
system was embedded in a truncated octahedron box of TIP3P water molecules with a 10 Å buffer 
along each dimension [59].
 To avoid edge effects, periodic boundary conditions were applied during 
the whole molecular dynamics (MD) simulation. Int. J. Mol. Sci. 2012, 13 2189 
 
 
3.2. Molecular Dynamics Simulations 
For each system, energy minimization and MD simulation were carried out using the sander module 
of the Amber 10 program. Before MD simulations, each system was subject to energy minimization in 
two stages to remove bad contacts between the complex and the solvent molecules. Firstly, the water 
molecules and counterions were minimized by freezing the solute using a harmonic constraint of a 
strength of 100 kcal·mol
−1·Å
−2. Secondly, each system was minimized without restriction. And each 
stage was performed using the steepest descent minimization of 1000 steps followed by a conjugate 
gradient minimization of 2000 steps. After the minimization, the system was then heated from 0 to  
300 K in 100 ps and equilibrated at 300 K for another 100 ps. Finally, we run MD simulations on each 
system at 1 atm and 300 K for 9 ns to make sure that a stable trajectory for each of the simulated 
structures was obtained. During the simulation, the SHAKE method was applied to constraint the 
covalent bonds involving hydrogen atoms [60]. The Particle Mesh Ewald (PME) method was used for 
calculating the long-range electrostatic interactions [61,62]. The cutoff distances for the long-range 
electrostatic and van der Waals energy terms were set to 10.0 Å. 
3.3. MM-GBSA Calculations 
For each complex, a total number of 200 snapshots were taken from the last 2 ns of the MD 
trajectory with an interval 10 ps. The MM-PB/SA method and nmod module, which is implemented in 
Amber10, were applied to compute the binding free energies of the inhibitors to MDM2/MDMX. In 
this approach, the binding free energies (ΔG) are approximated by 
ΔG = ΔGMM + ΔGsol − TΔS (1) 
where ΔGMM is standard molecular mechanical energy in gas phase, ΔGsol is the solvation free energy 
and TΔS is a term involving the entropy effect. The molecular mechanical energy (ΔGMM) can further 
be expressed as 
ΔGMM = ΔEint + ΔGvdw + ΔGele (2) 
where  ΔEint,  ΔGvdw and ΔGele represent the internal energy contribution from bonds, angles and 
torsions, the van der Waals and electrostatic interactions in gas phase, respectively. The solvation free 
energy (ΔGsol) is further divided into two components: 
ΔGsol = ΔGpol + ΔGnopol (3) 
where  ΔGpol and ΔGnopol are polar and non-polar contributions to the solvation free energy, 
respectively. The former component was computed using the modified GB model developed by 
Onufriev A et al. [48]. The dielectric constant inside the solute was set to 1.0 and 80.0 in the solvent in 
our calculations. Whereas the latter term was determined by 
ΔGnopol = γ SASA + β (4) 
where SASA is the solvent-accessible surface area and was calculated with the MSMS program [63]. 
In this work, the values for γ and β was set to 0.0072 kcal·mol
−1·Å
−2) and 0 kcal·mol
−1, respectively. 
The conformational entropies are important contributions to the inhibitor-receptor binding. Thus, 
normal-mode analysis was performed to compute the conformational entropy change upon the Int. J. Mol. Sci. 2012, 13 2190 
 
 
inhibitor binding. However, due to entropy calculations for large systems being extremely time 
consuming, we applied only 25 snapshots taken at an interval of 80 ps from the final 2 ns of the MD 
simulation to calculate the entropy contribution. Each snapshot was minimized with a distance-dependent 
dielectric function 4Rij (the distance between two atoms) until the root-mean-square of the energy 
gradient was lower than 10
−4 kcal·mol
−1·Å
−1. The calculation error bars are the standard errors of the 
mean (SE)calculated using equation 5, in which STD is a standard deviation and N is the number of 
trajectory snapshots used in the calculation [64]. 
STD
SE
N
   (5) 
3.4. Inhibitor-Residue Interaction Decomposition 
The inhibitor-residue interaction, which is valuable to qualitatively define the binding mechanisms 
of the four inhibitors to MDM2, was analyzed using a per-residue-based decomposition method [65] 
and approximated by: 
∆Ginhibitor-residue = ∆Gvdw + ∆Gele + ∆Ggb + ∆Gsurf (6) 
where  ∆Gvdw and ∆Gele are non-bonded van der Waals interactions and electrostatic interactions, 
respectively, between the inhibitor and each MDM2 residue in the gas phase and ∆Ggb and ∆Gsurf are 
the polar and non-polar contributions to the inhibitor-residue interaction, respectively. 
3.5. Computational Alanine Scanning Mutagensis 
To determine the contribution of each residue in the interaction interface of the inhibitor-receptor 
binding and to study the detailed mechanisms at the energetic and atomic levels, computational alanine 
scanning was carried out on MDM2/MDMX, and the binding free energies of the inhibitors to the 
protein mutants were calculated by using the MM-GBSA method. The alanine mutant structures were 
obtained by altering the coordinates of the wild-type trajectory, which involves cutting atoms and 
truncating the mutated residue at Cγ by replacing with a hydrogen atom [66]. All parameters in the 
topology files of the mutated residues were accordingly replaced by the alanine residue parameters. 
The same 200 snapshots taken from the last 2 ns of MD trajectory with the time interval of 10 ps were 
used to calculate free energy. The key residues of the MDM2: Lys51, Leu54, Leu56, Ile61 Met62, 
Tyr67, Val93, His96 and Ile99, and the key residues of MDMX: Lys50, Met53, Ile60, Met61, Tyr66, 
Val92 and Leu98 were chosen for mutation. However, due to the significant difference in backbone 
conformations between proline and alanine, the Pro95 from the active site of MDMX was not   
selected [66]. 
4. Conclusions 
In this work, MD simulation coupled with the MM-GBSA method has been carried out to probe the 
difference in the binding modes of the peptide and non-peptide inhibitors to MDM2/MDMX. The 
results confirm that the peptide inhibitors can produce more interaction contacts than the non-peptide 
inhibitors. The binding mode prediction of based-residue decomposition suggests that the π–π, CH–π 
and CH–CH interactions, dominated by the shape complementarity, govern the bindings of the Int. J. Mol. Sci. 2012, 13 2191 
 
 
inhibitors in the hydrophobic cleft of MDM2/MDMX. Lastly, we confirm that the existence of the 
potential steric clash formed by the residue Tyr99 due to energy and structure, make it possible to 
develop the potent dual inhibitors inhibiting the p53-MDM2/MDMX interaction. 
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